N
Novotech
Leading Contract Research Organization (CRO) in Australia, providing drug development consulting and clinical development services
About Novotech
Novotech CRO is a leading Contract Research Organization (CRO) specializing in providing comprehensive clinical research solutions worldwide. The company serves a diverse range of clients, including pharmaceutical, biotechnology, and medical device companies, primarily focusing on the Asia-Pacific region. Novotech operates in a highly competitive market, leveraging its extensive network of offices across key locations such as Australia, New Zealand, China, India, South Korea, and Southeast Asia to offer localized expertise and efficient regulatory navigation.
The business model of Novotech revolves around offering end-to-end clinical trial services, from initial study design and regulatory submissions to patient recruitment, data management, and final reporting. This full-service approach ensures that clients can conduct their clinical trials seamlessly, reducing time-to-market for new therapies and medical devices. Novotech generates revenue through service contracts with its clients, often structured as multi-year agreements that provide a steady stream of income.
Novotech's competitive edge lies in its deep understanding of the regulatory landscapes across the Asia-Pacific region, its robust operational infrastructure, and its commitment to quality and compliance. The company also emphasizes the use of real-world evidence and advanced data analytics to accelerate clinical trials, thereby enhancing the efficiency and effectiveness of the research process.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1996
- Headquarters
- Sydney, Australia
- Employees
- 2,140
- Open positions
- 80
- Dealroom signal
- 37.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Clinical Trials, Tech for Biotech and Pharma, Became $1B as Subsidiary, Biotech and Pharma, Hard Tech
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 5 companies, latest Jan 2023
- Capital deployed
- $31M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | Mar 2025 | $0 | — | TPG · Temasek · GIC | ↗ |
| GROWTH EQUITY VCOther financing | Jan 2022 | $255M | $3B | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Novotech is 62K monthly website visits, down 3.1% over the last three months. Novotech's team grew 3.1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
EastHORNWarsaw, Poland
→
CBR InternationalBoulder, United StatesTechnical consulting in fda representation, strategic program, process development & clinical program development
→
NCGSCharleston, United StatesInternational full-service cro, providing clinical development support to pharmaceutical, biotechnology
→
ProspectionSydney, AustraliaProvider of web development, google apps, sharepoint integration, statistical analysis, and web marketing
$180Mvaluation
ObvioHealthOrlando, United StatesGlobal digital health organization providing real-world digital clinical trials that deliver better data
$155Mvaluation
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Novotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Novotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.












